FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281740887> ?p ?o ?g. }

• W4281740887 endingPage "346" @default.
• W4281740887 startingPage "341" @default.
• W4281740887 abstract "To describe the effectiveness and safety of biologics for the treatment of relapsing and/or refractory polyarteritis nodosa (PAN).A retrospective European collaborative study was conducted in patients with PAN who received biologics for relapsing and/or refractory disease.Forty-two patients with PAN received a total of 53 biologic courses, including TNF-α blockers in 15 cases, rituximab (RTX) in 18 cases, tocilizumab (TCZ) in 10 cases and other biologics in 10 cases. TNF-α blockers and TCZ were mainly used for refractory diseases whereas RTX was mainly initiated for relapsing disease. After a median follow-up of 29 (8-50) months, remission, partial response, treatment failure and treatment discontinuation due to severe adverse events occurred in, respectively, 40%, 13%, 40% and 7% of patients receiving TNF-α blockers, 50%, none, 30% and 20% of TCZ recipients, and 33%, 11%, 56% and none of the RTX recipients. No remission was noted in patients treated with other biologics. Severe adverse events were observed in 14 (28%) patients without significant differences between the three biologics, leading to early biologics discontinuation in only three cases.These results suggest that TCZ may be effective in relapsing and/or refractory PAN. Our data warrant further study to confirm these findings." @default.
• W4281740887 created "2022-06-13" @default.
• W4281740887 creator A5003504837 @default.
• W4281740887 creator A5003714626 @default.
• W4281740887 creator A5007777664 @default.
• W4281740887 creator A5007993716 @default.
• W4281740887 creator A5009072437 @default.
• W4281740887 creator A5010707925 @default.
• W4281740887 creator A5012892075 @default.
• W4281740887 creator A5013406612 @default.
• W4281740887 creator A5014700089 @default.
• W4281740887 creator A5019444164 @default.
• W4281740887 creator A5020315046 @default.
• W4281740887 creator A5020594616 @default.
• W4281740887 creator A5022555111 @default.
• W4281740887 creator A5027134318 @default.
• W4281740887 creator A5027268725 @default.
• W4281740887 creator A5027512145 @default.
• W4281740887 creator A5029298966 @default.
• W4281740887 creator A5040519190 @default.
• W4281740887 creator A5043386582 @default.
• W4281740887 creator A5044242352 @default.
• W4281740887 creator A5047584127 @default.
• W4281740887 creator A5054350853 @default.
• W4281740887 creator A5056973236 @default.
• W4281740887 creator A5067996191 @default.
• W4281740887 creator A5070674274 @default.
• W4281740887 creator A5082190748 @default.
• W4281740887 date "2022-06-10" @default.
• W4281740887 modified "2023-10-13" @default.
• W4281740887 title "Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study" @default.
• W4281740887 cites W2031517139 @default.
• W4281740887 cites W2053251763 @default.
• W4281740887 cites W2086314050 @default.
• W4281740887 cites W2120427700 @default.
• W4281740887 cites W2278411346 @default.
• W4281740887 cites W2769949274 @default.
• W4281740887 cites W2890089963 @default.
• W4281740887 cites W2936750573 @default.
• W4281740887 cites W2939996163 @default.
• W4281740887 cites W3033622153 @default.
• W4281740887 cites W3116551151 @default.
• W4281740887 cites W3130285039 @default.
• W4281740887 cites W4230852346 @default.
• W4281740887 doi "https://doi.org/10.1093/rheumatology/keac332" @default.
• W4281740887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35686919" @default.
• W4281740887 hasPublicationYear "2022" @default.
• W4281740887 type Work @default.
• W4281740887 citedByCount "1" @default.
• W4281740887 countsByYear W42817408872023 @default.
• W4281740887 crossrefType "journal-article" @default.
• W4281740887 hasAuthorship W4281740887A5003504837 @default.
• W4281740887 hasAuthorship W4281740887A5003714626 @default.
• W4281740887 hasAuthorship W4281740887A5007777664 @default.
• W4281740887 hasAuthorship W4281740887A5007993716 @default.
• W4281740887 hasAuthorship W4281740887A5009072437 @default.
• W4281740887 hasAuthorship W4281740887A5010707925 @default.
• W4281740887 hasAuthorship W4281740887A5012892075 @default.
• W4281740887 hasAuthorship W4281740887A5013406612 @default.
• W4281740887 hasAuthorship W4281740887A5014700089 @default.
• W4281740887 hasAuthorship W4281740887A5019444164 @default.
• W4281740887 hasAuthorship W4281740887A5020315046 @default.
• W4281740887 hasAuthorship W4281740887A5020594616 @default.
• W4281740887 hasAuthorship W4281740887A5022555111 @default.
• W4281740887 hasAuthorship W4281740887A5027134318 @default.
• W4281740887 hasAuthorship W4281740887A5027268725 @default.
• W4281740887 hasAuthorship W4281740887A5027512145 @default.
• W4281740887 hasAuthorship W4281740887A5029298966 @default.
• W4281740887 hasAuthorship W4281740887A5040519190 @default.
• W4281740887 hasAuthorship W4281740887A5043386582 @default.
• W4281740887 hasAuthorship W4281740887A5044242352 @default.
• W4281740887 hasAuthorship W4281740887A5047584127 @default.
• W4281740887 hasAuthorship W4281740887A5054350853 @default.
• W4281740887 hasAuthorship W4281740887A5056973236 @default.
• W4281740887 hasAuthorship W4281740887A5067996191 @default.
• W4281740887 hasAuthorship W4281740887A5070674274 @default.
• W4281740887 hasAuthorship W4281740887A5082190748 @default.
• W4281740887 hasConcept C121332964 @default.
• W4281740887 hasConcept C126322002 @default.
• W4281740887 hasConcept C141071460 @default.
• W4281740887 hasConcept C142424586 @default.
• W4281740887 hasConcept C197934379 @default.
• W4281740887 hasConcept C2777178219 @default.
• W4281740887 hasConcept C2778715236 @default.
• W4281740887 hasConcept C2779134260 @default.
• W4281740887 hasConcept C2779338263 @default.
• W4281740887 hasConcept C2780653079 @default.
• W4281740887 hasConcept C71924100 @default.
• W4281740887 hasConcept C87355193 @default.
• W4281740887 hasConcept C90924648 @default.
• W4281740887 hasConceptScore W4281740887C121332964 @default.
• W4281740887 hasConceptScore W4281740887C126322002 @default.
• W4281740887 hasConceptScore W4281740887C141071460 @default.
• W4281740887 hasConceptScore W4281740887C142424586 @default.
• W4281740887 hasConceptScore W4281740887C197934379 @default.
• W4281740887 hasConceptScore W4281740887C2777178219 @default.
• W4281740887 hasConceptScore W4281740887C2778715236 @default.
• W4281740887 hasConceptScore W4281740887C2779134260 @default.

• next